Introduction
============

Lung cancer is a leading cause of cancer death worldwide, and the median survival time (MST) of patients with advanced lung cancer was reported to be around 1 year in the early 2000s, even if they were treated with standard therapies such as platinum-based chemotherapy followed by docetaxel.^[@r01])^ Gefitinib, the first epidermal growth factor receptor (*EGFR*) tyrosine kinase inhibitor (TKI), was approved in 2002 in Japan for advanced non-small cell lung cancer (NSCLC), which accounts for about 80% of all lung cancers. However, the response rate and progression-free survival (PFS) with gefitinib as a second-line treatment for unselected NSCLC patients was 18% and 2.7 months, respectively, which did not differ from docetaxel.^[@r02])^ Additionally, the IRESSA Survival Evaluation in Lung Cancer trial conducted in western countries demonstrated that gefitinib did not improve overall survival (OS) of patients with NSCLC compared with placebo.^[@r03])^ Gefitinib was also associated with a risk of severe drug-induced fatal interstitial lung disease (ILD),^[@r04])^ which was later found to be a particularly high risk in Japanese patients.^[@r05])^ Thus gefitinib was not recommended for use in Japan at this time.

The identification of *EGFR* somatic mutations changed the situation dramatically. Mutations such as exon 19 deletions and L858R in exon 21 in the *EGFR* coding domain identified in tumor specimens from patients with NSCLC who experienced a good response to gefitinib were revealed to cause excessive tumor growth by autophosphorylation of the EGFR downstream signal cascade.^[@r06])^ The mutations highly linked with "oncogene addiction" were later recognized as "driver mutations", and pivotal pre-clinical research suggested that the blockade of EGFR signaling by specific TKIs caused a durable response of NSCLC with *EGFR* mutations.^[@r07])^ This review examines the progress that has been made in EGFR-TKI treatment for *EGFR*-mutated NSCLC.

EGFR-TKI monotherapy for *EGFR*-mutated NSCLC
=============================================

Soon after a retrospective report of a durable response to gefitinib in patients with *EGFR*-mutated NSCLC,^[@r06])^ we conducted a small phase II study of gefitinib in Tohoku University Hospital. It was the first prospective study to evaluate the efficacy and safety of gefitinib as first-line treatment for advanced NSCLC with *EGFR* mutations. Mutations were identified by DNA direct sequencing before treatment commenced. At this time, concern had been raised about gefitinib treatment causing drug-induced ILD, which occurred more frequently among Japanese patients than in those from western countries.^[@r05])^ However, the high effectiveness of the treatment for this population, including a response rate of 75% and a PFS of around 10 months, dispelled concerns from a risk--benefit balance viewpoint.^[@r08])^ This marked the beginning of individualized treatment for advanced NSCLC. Another phase II study, NEJ001, conducted by the North-East Japan Study Group (NEJSG) reported that gefitinib monotherapy was highly effective with acceptable toxicities even for *EGFR*-mutated NSCLC patients with poor performance status (PS; 3--4) who had not been recommended for standard chemotherapy.^[@r09])^ These results were described as the "Lazarus Response" in an editorial.^[@r10])^

Since our report, several phase II studies conducted in Japan have also demonstrated good results with gefitinib, and these were eventually combined into the I-CAMP study.^[@r11])^ In this analysis, the combined data of patients treated with gefitinib were retrospectively compared with those of patients treated with standard platinum-based chemotherapy. Results suggested that gefitinib was superior to standard chemotherapy (median PFS of the gefitinib group and chemotherapy group, 10.7 and 6 months, respectively; p \< 0.001). Based on these promising results of EGFR-TKI monotherapy, the NEJSG group conducted a multi-centered prospective phase III study, NEJ002, which compared gefitinib with standard chemotherapy (carboplatin \[CBDCA\] plus paclitaxel \[PTX\]) as the first-line treatment for advanced *EGFR*-mutated NSCLC. This used the highly sensitive peptide nucleic acid-locked nucleic acid PCR clamp method, developed by Dr. Hagiwara, to detect *EGFR* mutations from small samples such as sputum or effusions.^[@r12])^ Enrolment in the study was successful due to the introduction of this PCR-based method, because sufficient tumor samples were often not obtained from patients with inoperable advanced NSCLC. NEJ002 revealed that gefitinib was significantly better than standard chemotherapy in terms of response rate, PFS, and quality of life (QOL).^[@r13],[@r14])^ Although the OS did not different between groups, this less toxic novel therapy was accepted as the new standard treatment for *EGFR*-mutated NSCLC. At the same time as NEJ002, another phase III study, I-PASS, compared gefitinib with CBDCA+PTX for advanced NSCLC patients with some favorable characteristics for EGFR-TKI such as adenocarcinoma histology and non/light smoking history. Subgroup analysis of I-PASS clearly showed that patient selection by *EGFR* mutation status was much better than by the abovementioned clinical features.^[@r15])^

Subsequently, the WJTOG3405 study reported the superiority of gefitinib compared with standard cisplatin plus docetaxel.^[@r16])^ Similar comparative studies conducted outside Japan also demonstrated that gefitinib or erlotinib, another EGFR-TKI, were superior to standard chemotherapy; EGFR-TKI then became the new standard first-line treatment for advanced NSCLC patients with *EGFR* mutations (Table [1](#tbl01){ref-type="table"}).^[@r17],[@r18])^ A few years later, afatinib and dacomitinib were developed as second-generation EGFR-TKIs capable of blocking signal cascades not only from EGFR (ErbB1) but also other ErbB families (ErbB2-4) irreversibly. Afatinib was revealed to be superior to standard chemotherapy with respect to PFS in two phase III studies, and dacomitinib demonstrated superiority to gefitinib regarding PFS and OS in the ARCHER study.^[@r19]--[@r21])^ Osimertinib, the third-generation EGFR-TKI that conquered a T790M-resistant mutation, an acquired gene mutation in tumors resistant to first- and second-generation EGFR-TKIs, was initially approved for *EGFR*-mutated NSCLC with T790M after the first- or second-generation EGFR-TKI treatment based on positive results of the AURA3 study.^[@r22])^ Recently it also showed significant superiority to gefitinib and erlotinib with respect to PFS and OS as the first-line treatment for *EGFR*-mutated NSCLC in the FLAURA study.^[@r23])^ Osimertinib has another advantage of being effective in brain metastasis.^[@r24])^ Because osimertinib is less toxic than first-generation EGFR-TKIs regarding subjective adverse events such as skin rash, paronychia, and diarrhea, it is currently accepted as the new standard first-line treatment for *EGFR*-mutated advanced NSCLC.

Development of combined therapy with EGFR-TKI for *EGFR*-mutated NSCLC
======================================================================

Post-hoc analysis of NEJ002 revealed that more than 30% of patients treated with gefitinib as first-line treatment did not receive subsequent treatment with platinum agents, whereas 98% of patients treated with first-line chemotherapy received gefitinib; this was one reason why the first-line gefitinib group did not improve their OS compared with the first-line chemotherapy group.^[@r25])^ The analysis also suggested that patients who received EGFR-TKI, platinum agents, and pemetrexed (PEM; a novel standard agent for non-squamous NSCLC) achieved a longer OS than those who received EGFR-TKI and platinum agents without PEM. Thus, we hypothesized that "using up" these important three key drugs (EGFR-TKI, platinum agents, and PEM) may improve the OS of patients with *EGFR*-mutated NSCLC.

NEJ005, a randomized phase II study that compared two different schedules of EGFR-TKI and chemotherapy combination, was initiated in 2010. It demonstrated similar efficacies for both the concurrent group (gefitinib, CBDCA, and PEM concurrently) and the alternating group (2 cycles of alternating gefitinib alone and chemotherapy with CBDCA plus PEM followed by PEM alone every 8 weeks) with response rates and PFS of 88% and 18.3 months and 85% and 15.3 months, respectively. Safety levels as measured by the incidence of ≥grade 3 toxicities were similar between groups and there were no treatment-related deaths in either group.^[@r26])^ Moreover, the OS was longer in the concurrent group and the schedule because this was much easier in general practice; therefore, we selected the concurrent regimen for an experimental treatment in a subsequent large phase III study, NEJ009.^[@r27])^

NEJ009 was the first phase III trial that compared a combination regimen with EGFR-TKI and chemotherapy with EGFR-TKI alone for untreated advanced NSCLC with *EGFR* mutations. In this trial, the combination group demonstrated a significantly longer PFS and OS than the gefitinib monotherapy group (Table [2](#tbl02){ref-type="table"}).^[@r27])^ Although the overall frequency of toxicities in the combination group was more than in the monotherapy group, the frequency of treatment-related severe toxicities and treatment discontinuation caused by toxicity did not differ, and neither did the QOL evaluation. At a similar time to the NEJ009 report, another phase III study conducted in India compared the same regimens for *EGFR*-mutated NSCLC, and also found that the combination regimen was superior to gefitinib alone.^[@r28])^ Additionally, the latest OS analysis from the FLAURA study reported an MST for first-line osimertinib (the current global standard) of 38.8 months.^[@r29])^ Based on the above evidence, a strategy of recommending the NEJ009 regimen for patients with a good PS who can tolerate enhanced toxicities to achieve a longer OS could be reasonable. Although osimertinib is still appropriate for patients who prefer a less toxic regimen, especially those with a poor PS and/or symptomatic brain metastases (Fig. [1](#fig01){ref-type="fig"}).

Another combination with EGFR-TKIs and an anti-angiogenic agent has also been investigated. Based on promising results from a randomized phase II study, a combination regimen with erlotinib and bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody that binds and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, was compared with erlotinib alone in a phase III trial, NEJ026. This showed that the combination regimen achieved a significantly longer PFS than erlotinib alone.^[@r30])^ Additionally, the RELAY study that compared a combination of erlotinib and ramucirumab, a human monoclonal IgG1 antibody that selectively targets VEGFR2, demonstrated that the combination regimen also achieved a significantly longer PFS than erlotinib alone (Table [2](#tbl02){ref-type="table"}).^[@r31])^ Although these combinations are promising treatments for *EGFR*-mutated NSCLC, the OS results are still immature, so their clinical benefit is currently unclear.

Future perspectives of treatments for *EGFR*-mutated NSCLC
==========================================================

There are some clinical questions regarding treatments with EGFR-TKI for *EGFR*-mutated NSCLC. First, because no direct comparison between osimertinib and the NEJ009 regimen has been carried out, the true superiority is unknown. Although patient selection considering the risk--benefit balance is recommended, further evidence is awaited. Second, the benefit of a promising combination of osimertinib and chemotherapy is still unknown, although this should be elucidated by the ongoing FLAURA2 phase III study comparing a combination of osimertinib with CBDCA and PEM to osimertinib alone (NCT04035486).^[@r32])^ Third, the usefulness of immune checkpoint inhibitors for *EGFR*-mutated NSCLC is also unknown. Although a subgroup analysis of the IMPOWER150 study suggested that a combination regimen with atezolizumab, CBDCA, paclitaxel, and bevacizumab was effective for *EGFR*-mutated NSCLC, prospective validation of this is urgently needed.^[@r33])^ By overcoming these problems, it is expected that therapy for *EGFR*-mutated NSCLC will be further improved.
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![Current treatment strategy for *EGFR*-mutated advanced NSCLC. A sequence of first-line osimertinib followed by platinum-based chemotherapy (Pl), and second-line chemotherapy (2L) such as docetaxel and other treatments (Tx) including best supportive care alone, which demonstrated overall survival of around 38 months, is recommended for patients who prefer a less toxic standard regimen (upper line). Another sequence with the first-line NEJ009 regimen including carboplatin (CBDCA), pemetrexed (PEM), and gefitinib followed by osimertinib (only available when T790M mutation was detected), 2L, and other Tx had the potential to achieve an overall survival of around 50 months and is recommended for patients with good performance status (lower line). The length of each bar in the figure indicates PFS presented in previous phase III studies such as AURA3 (second-line osimertinib) or FLAURA (first-line osimertinib).](pjab-96-266-g001){#fig01}

###### 

Phase III studies of EGFR-TKI monotherapy as the first-line treatment for *EGFR*-mutated NSCLC

  Name of study^reference^ (number of patients)   EGFR-TKI Compared treatment   RR (%)   PFS (m)    HR (95%CI) p value   OS (m)   HR (95%CI) p value
  ----------------------------------------------- ----------------------------- -------- ---------- -------------------- -------- ----------------------
  IPASS (subgroup analysis)^[@r14])^ (n = 261)    gefitinib                     71       9.5        0.48 (0.36--0.64)    18.6     0.91 (0.76--1.10)
  CBDCA+PTX                                       47                            6.3      \<0.001    17.3                 NA       
  NEJ002^[@r13])^ (n = 230)                       gefitinib                     74       10.8       0.30 (0.22--0.41)    27.7     0.89 (0.63--1.24)
  CBDCA+PTX                                       31                            5.4      \<0.001    26.6                 NA       
  WJTOG3405^[@r16])^ (n = 172)                    gefitinib                     62       9.2        0.49 (0.34--0.71)    36.5     1.19 (0.77--1.83)
  CDDP+DOC                                        32                            6.3      \<0.0001   36.8                 NA       
  OPTIMAL^[@r17])^ (n = 165)                      erlotinib                     83       13.7       0.16 (0.11--0.26)    22.7     1.04 (0.69--1.58)
  CBDCA+GEM                                       36                            4.6      \<0.0001   28.9                 NA       
  EURTAC^[@r18])^ (n = 174)                       erlotinib                     61       9.7        0.37 (0.25--0.54)    19.3     1.04 (0.65--1.68)
  platinum-doublet                                18                            5.2      \<0.0001   19.5                 NA       
  LUX-Lung3^[@r19])^ (n = 345)                    afatinib                      61       13.6       0.47 (0.34--0.65)    28.2     0.88 (NA)
  CDDP+PEM                                        22                            6.9      \<0.0001   28.2                 0.385    
  LUX-Lung6^[@r20])^ (n = 363)                    afatinib                      74       11.0       0.28 (0.20--0.39)    23.1     0.93 (NA)
  CDDP+GEM                                        31                            5.6      \<0.0001   23.5                 0.6137   
  ARCHER^[@r21])^ (n = 452)                       dacomitinib                            14.7       0.59 (0.47--0.74)    34.1     0.760 (0.582--0.993)
  gefitinib                                                                     9.2      \<0.0001   26.8                 0.044    
  FLAURA^[@r23],[@r29])^ (n = 556)                osimertinib                   80       18.9       0.46 (0.37--0.57)    38.6     0.799 (0.641--0.997)
  gefitinib or erlotinib                          76                            10.2     \<0.0001   31.8                 0.0462   

RR, response rate; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; CBDCA, carboplatin; PTX, paclitaxel; CDDP, cisplatin; DOC, docetaxel; GEM, gemcitabine; PEM, pemetrexed; NA, not available.

###### 

Phase III studies of combined regimen with EGFR-TKI as the first-line treatment for *EGFR*-mutated NSCLC

  Name of study^reference^ (number of patients)   Combined regimen Compared treatment   RR (%)   PFS (m)    HR (95%CI) p value     OS (m)     HR (95%CI) p value
  ----------------------------------------------- ------------------------------------- -------- ---------- ---------------------- ---------- --------------------
  EGFR-TKI combined with cytotoxic agents                                                                                                     
  NEJ009^[@r27])^ (n = 345)                       gefitinib+CBDCA+PEM                   71       20.9       0.49 (0.39--0.62)      50.9       0.72 (0.55--0.95)
  gefitinib                                       47                                    11.2     \<0.001    38.8                   0.021      
  Noronha's study^[@r28])^ (n = 350)              gefitinib+CBDCA+PEM                   74       16         0.51 (0.39--0.66)      NR         0.45 (0.31--0.65)
  gefitinib                                       31                                    8        \<0.0001   17                     \<0.0001   
                                                                                                                                              
  EGFR-TKI combined with anti-angiogenic agent                                                                                                
  NEJ026^[@r30])^ (n = 228)                       erlotinib+bevacizumab                 61       16.9       0.605 (0.417--0.877)   28.2       0.88
  erlotinib                                       22                                    13.3     0.016      28.2                   0.385      
  RELAY^[@r31])^ (n = 449)                        erlotinib+ramucirumab                 74       19.4       0.591 (0.461--0.760)   NR         0.83 (0.53--1.30)
  erlotinib                                       31                                    12.4     \<0.0001   NR                     NA         

RR, response rate; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; CBDCA, carboplatin; PEM, pemetrexed; NR, not reached; NA, not available.
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